Literature DB >> 32391998

[The first 29 COVID-19-patients in a clinic: early experiences from a Dutch hospital].

N Van der Moeren1,2, S Talman3, W van den Bijllaardt1, M Kant3, P Heukels3, R G Bentvelsen1, D W Loth3.   

Abstract

The SARS-CoV-2 virus and COVID-19 disease is of pandemic proportions and reached the Netherlands on February 27 2020. Here we present the first Dutch cohort of 29 hospitalized patients during the first two weeks of the epidemic in the Netherlands. Demographic characteristics of patients, clinical presentation and course of disease up to the moment of analysis showed similarity with what has been described in Chinese and Italian literature. However the higher proportion of patients presenting with gastro-intestinal symptoms and the high number of patients with overweight and obesity stood out. Based on the experience in our hospital very early on in the epidemic COVID-19 impresses as a severe illness with risk of acute respiratory deterioration.

Entities:  

Mesh:

Year:  2020        PMID: 32391998

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave.

Authors:  Robbert G Bentvelsen; Andreas L E Van Arkel; Tom A Rijpstra; Merijn K M Kant; Simone Van Der Sar-Van Der Brugge; Daan W Loth; Peter Van Wijngaarden; Arthur W F Du Mée; David C Y Yick; Bram M W Diederen; Peter C Wever; Alexander C A P Leenders; Laura Van Dommelen; Klaas H De Groot; Wouter Van den Bijllaardt; Paul E Verweij
Journal:  J Fungi (Basel)       Date:  2022-01-19

2.  Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline.

Authors:  Elske Sieswerda; Mark G J de Boer; Marc M J Bonten; Wim G Boersma; René E Jonkers; Roel M Aleva; Bart-Jan Kullberg; Jeroen A Schouten; Ewoudt M W van de Garde; Theo J Verheij; Menno M van der Eerden; Jan M Prins; W Joost Wiersinga
Journal:  Clin Microbiol Infect       Date:  2020-10-01       Impact factor: 8.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.